Metformine Eg (Metformin Hydrochloride)

Metformin reduces hepatic glucose production by activating AMP‑activated protein kinase, increases peripheral glucose uptake, and modestly decreases intestinal glucose absorption. These actions together lower blood glucose levels without stimulating insulin secretion.

The dose of Metformine Eg is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

The safety of metformin in pregnancy is not fully established; it should only be used if the potential benefit justifies the potential risk. Metformin is excreted in breast milk, so a healthcare professional should evaluate the risk‑benefit ratio for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Metformine Eg belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, and SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not cause hypoglycemia when used alone and has a favorable effect on weight and cardiovascular risk profiles.

Metformine Eg should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children.

Metformine Eg is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water; they are not intended for crushing or chewing unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with renal or hepatic impairment, severe infection, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformine Eg is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving radiographic contrast studies that may affect kidney function.